The pharmaceutical company rode one copycat drug to record profits. Now, co-chairman G.V. Prasad has to prove the company can grow without it. Biosimilars and innovation may hold the answer.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.